CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection

The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.

Related Videos
Experts on DTC
Yael Cohen, MD
Adam D. Cohen, MD, director, Myeloma Immunotherapy, associate professor in medicine, hematology/oncology, Abramson Cancer Center, University of Pennsylvania
Experts on lung cancer
Jeffery Zonder, MD
Natalie S. Callander, MD
Experts on DTC
Experts on DTC
Jeffery Zonder, MD
Expert on lung cancer
Related Content